Vikas Lifecare Q3 FY26 results: income falls, loss narrows

Stock snapshot and why the update matters

Vikas Lifecare Ltd. was trading at ₹1.49 on Wed, Jun 24, 2026 at 08:03:50, as per the provided market snapshot. The company has also been making a series of regulatory disclosures around its financial results, including newspaper advertisements and submissions to the exchanges. These updates matter because they help investors track how the company’s quarterly performance has changed versus the previous quarter, and how quickly it is publishing results and related compliance documents.

The data in the feed also flags peer moves for context. Listed peers mentioned include PG Electroplast (-1.69%), Astral (0.81%), and Supreme Industries (1.10%).

What the company published and where it was reported

Vikas Lifecare published newspaper advertisements of its Q3 FY26 unaudited financial results in Financial Express and Jansatta dated April 24 and 25, 2026. The company submitted copies of these newspaper advertisements to NSE and BSE on April 25, 2026.

The results were approved by the Board of Directors at its meeting held on April 21, 2026, following review by the Audit Committee, and were accompanied by a statutory auditor’s limited review. The disclosure also notes the results were digitally signed by Managing Director Sundeep Kumar Dhawan (DIN: 09508137).

Q3 FY26: consolidated loss reported for Dec 2025 quarter

For the quarter ended December 31, 2025 (Q3 FY26), the company’s published figures show a consolidated loss, with standalone numbers also in the red. The table shared in the disclosures reports Total Income, Total Expenses, Profit/(Loss) Before Tax, Net Profit/(Loss), and EPS.

A separate line in the feed summarises Q3 performance as well, stating Q3 Dec 2025 revenue of ₹97.0293 crore, down from ₹141.3266 crore in Q2 Sep 2025. This is directionally consistent with the Total Income comparison shown in the company’s results table.

Q2 FY26 comparison: “last quarter” loss figure in context

The dataset states the company posted a net profit of -₹118.95 crore in its last quarter. This aligns with the company’s Q2 FY26 consolidated net loss shown in the results table as ₹11,896.04 lakh, which converts to -₹118.9604 crore.

In Q3 FY26, the consolidated net loss reported is ₹2,927.64 lakh, or -₹29.2764 crore, indicating a significantly smaller loss versus Q2 FY26 on the consolidated line. The same table shows Q2 FY26 consolidated EPS at 0.03, while Q3 FY26 consolidated EPS is -0.04.

Key financial table (all amounts normalised to ₹ crore)

Nine-month performance disclosed up to Dec 31, 2025

For the nine months ended December 31, 2025, Vikas Lifecare reported total income of ₹46,560.00 lakh (₹465.60 crore) on a consolidated basis and ₹45,949.12 lakh (₹459.4912 crore) on a standalone basis.

The summary in the feed also cites a nine-month revenue figure of ₹330.7395 crore for the nine months ended Dec 2025, compared with ₹344.8178 crore in the same period last year. This is presented as a revenue comparison, while the company’s results table provides “total income”, so readers should treat these as separate line items as disclosed.

Additional quarterly snapshot in the feed (Q1 FY25-26)

Another section of the provided data references a “Last Earnings Date” of Q1 FY25-26, 14th Aug, 2025, and reports:

• Revenue: ₹97 crore
• Gross profit: -₹17 crore
• Net profit: -₹14 crore

The same feed also repeats that the company reported net profit of ₹-14 and revenue earned of ₹97. These figures are presented without a separate table in the input, but they match the Q1 snapshot shown alongside QoQ and YoY percentage changes.

Corporate actions: postal ballot for warrants and capital increase

Vikas Lifecare has issued a postal ballot notice seeking shareholder approval through remote e-voting for three resolutions. The resolutions include:

1. Issuance of 61,90,62,500 convertible warrants worth ₹99,05,00,000 (₹99.05 crore) to promoters and public investors.
2. Alteration of the Articles of Association for future capital issuance.
3. Increase in authorised share capital from ₹235 crore to ₹300 crore.

These proposals, if approved, would change the company’s capital structure and authorised limits, as described in the disclosure.

Trading window and results timeline references

The feed includes trading window updates stating the trading window has been closed since October 1, 2025, linked to pending finalisation and disclosure of unaudited Q2 FY2026 results (quarter ended September 30, 2025). It also states the window would reopen 48 hours after the unaudited results are declared, while noting delays because results were not yet finalised at that time.

Separately, a board meeting schedule reference mentions a meeting set for November 14, 2025 to discuss financial and operational matters, including approval of unaudited financial results for the quarter and half year ended September 30, 2025.

Market impact

From the disclosed numbers, the most direct market-relevant point is the quarter-on-quarter change between Q2 FY26 consolidated net loss of -₹118.9604 crore and Q3 FY26 consolidated net loss of -₹29.2764 crore, alongside a decline in income from ₹142.1910 crore to ₹97.7581 crore. This combination indicates lower scale of operations (based on total income) but a smaller reported loss compared with the immediately preceding quarter.

The stock price data point of ₹1.49 (Jun 24, 2026) provides a reference for where the market is valuing the company around the time the audited-results tag appears in the feed. Peer price moves cited in the snapshot show mixed trading in related listed names on the same reference, with one peer in the red and two in the green.

Analysis: what to watch in the disclosures

The company’s Q3 FY26 publication is notable for the compliance trail: board approval on April 21, 2026, publication in two newspapers on April 24 and 25, and submission to exchanges on April 25. That sequence helps investors validate that the results were circulated under Regulation 47 of SEBI (LODR) Regulations, 2015, as mentioned.

On fundamentals, the disclosed table indicates that expenses exceeded income in both Q3 FY26 consolidated and standalone numbers, resulting in losses. The comparison to Q2 FY26 suggests a material narrowing of the consolidated loss, even as total income declined. Separately, the postal ballot seeking approval for warrants worth ₹99.05 crore and an authorised capital increase to ₹300 crore signals the company is simultaneously working on capital and funding related resolutions.

Conclusion

Vikas Lifecare’s published Q3 FY26 unaudited results show lower total income versus Q2 FY26 and a reduced consolidated loss compared with the previous quarter’s -₹118.95 crore level cited in the feed. Alongside the financials, the company has disclosed a postal ballot for warrants and a proposed authorised capital increase, and has documented its newspaper and exchange filings for the results publication. The next dated event referenced in the dataset is the 14 Aug, 2025 earnings date entry, while investors will also track the outcomes and timelines tied to the postal ballot resolutions and related exchange updates.